In the April–June 2018 edition of Corporate Disputes, Dr. Gregory K. Bell discusses recent litigation involving companies operating in the pharmaceutical and medical device sector and the factors driving them. In this roundtable discussion, the panel experts explain the main issues and challenges these types of companies face during the litigation process. To read the article, click the download button to the right.
Keytruda and PD(L)1: Life after programmed death (part 2)
Looking ahead, we see a proliferation of PD-(L)1’s role; particularly in uses that go beyond traditional monoclonal, single-target antibodies (mAbs). Not only...